NCT01418937View on ClinicalTrials.gov

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

May 29, 2012

Primary Completion Date

January 9, 2015

Study Completion Date

January 9, 2015

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

CervarixTM (GSK580299)

Three intramuscular injections

Trial Locations (5)

90035003

GSK Investigational Site, Porto Alegre

13083-970

GSK Investigational Site, Campinas

80060-150

GSK Investigational Site, Curitiba

60135-225

GSK Investigational Site, Fortaleza

03015000

GSK Investigational Site, São Paulo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01418937 - Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study | Biotech Hunter | Biotech Hunter